Nifty
:
22402.40
Sensex
:
73852.94
34.40 (0.15%)
114.49 (0.16%)
Nifty
Sensex
:
:
22402.40
73852.94
34.40 (0.15%)
114.49 (0.16%)

Biocon Ltd.

Pharmaceuticals & Drugs - Global

Rating :
55/99

BSE: 532523 | NSE: BIOCON

NSE BSE
280.15
23-Apr-2024
  • Open
  • High
  • Low
  • Previous Close
  •  275.00
  •  281.00
  •  271.30
  •  271.15
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  10392195
  •  28763.01
  •  307.10
  •  217.50

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 33,658.82
  • 28.04
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 49,493.72
  • 0.54%
  • 1.70

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 60.64%
  • 1.46%
  • 15.53%
  • FII
  • DII
  • Others
  • 5.63%
  • 13.58%
  • 3.16%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.53
  • 15.17
  • 16.09

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.92
  • 13.53
  • 10.23

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 1.12
  • -12.54
  • -17.36

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 58.85
  • 62.49
  • 62.92

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.98
  • 4.69
  • 3.77

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 22.51
  • 20.46
  • 17.58

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 23
Dec 22
Var%
Sep 23
Sep 22
Var%
Jun 23
Jun 22
Var%
Mar 23
Mar 22
Var%
Net Sales
3,953.70
2,941.10
34.43%
3,462.30
2,319.70
49.26%
3,422.60
2,139.50
59.97%
3,773.90
2,408.80
56.67%
Expenses
3,026.90
2,296.80
31.79%
2,720.70
1,849.00
47.14%
2,708.20
1,740.10
55.63%
2,776.60
1,816.90
52.82%
EBITDA
926.80
644.30
43.85%
741.60
470.70
57.55%
714.40
399.40
78.87%
997.30
591.90
68.49%
EBIDTM
23.44%
21.91%
21.42%
20.29%
20.87%
18.67%
26.43%
24.57%
Other Income
565.50
78.60
619.47%
157.90
64.50
144.81%
93.50
77.90
20.03%
154.90
67.30
130.16%
Interest
266.70
120.30
121.70%
247.70
30.00
725.67%
233.00
19.90
1,070.85%
248.80
10.50
2,269.52%
Depreciation
414.50
301.10
37.66%
389.30
230.80
68.67%
358.00
217.50
64.60%
363.70
212.20
71.39%
PBT
832.30
30.10
2,665.12%
238.50
257.40
-7.34%
216.90
239.90
-9.59%
536.70
395.50
35.70%
Tax
54.90
-4.80
-
41.60
147.30
-71.76%
34.80
29.50
17.97%
82.10
58.60
40.10%
PAT
777.40
34.90
2,127.51%
196.90
110.10
78.84%
182.10
210.40
-13.45%
454.60
336.90
34.94%
PATM
19.66%
1.19%
5.69%
4.75%
5.32%
9.83%
12.05%
13.99%
EPS
5.50
-0.35
-
1.05
0.39
169.23%
0.84
1.20
-30.00%
2.61
1.99
31.16%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Net Sales
14,612.50
11,174.20
8,184.00
7,143.10
6,300.50
5,514.40
4,123.40
3,891.10
3,347.40
3,089.80
2,877.30
Net Sales Growth
48.97%
36.54%
14.57%
13.37%
14.26%
33.73%
5.97%
16.24%
8.34%
7.39%
 
Cost Of Goods Sold
4,797.20
3,663.10
2,718.40
2,243.70
1,989.50
1,896.60
1,636.10
1,446.60
1,290.40
1,255.60
1,186.10
Gross Profit
9,815.30
7,511.10
5,465.60
4,899.40
4,311.00
3,617.80
2,487.30
2,444.50
2,057.00
1,834.20
1,691.20
GP Margin
67.17%
67.22%
66.78%
68.59%
68.42%
65.61%
60.32%
62.82%
61.45%
59.36%
58.78%
Total Expenditure
11,232.40
9,054.70
6,691.40
5,841.00
5,043.50
4,390.60
3,294.30
2,911.60
2,584.30
2,394.00
2,190.20
Power & Fuel Cost
-
414.80
316.40
270.30
246.10
239.80
189.00
156.40
184.70
176.70
162.40
% Of Sales
-
3.71%
3.87%
3.78%
3.91%
4.35%
4.58%
4.02%
5.52%
5.72%
5.64%
Employee Cost
-
2,181.00
1,880.10
1,741.00
1,458.80
1,165.30
931.10
747.00
610.10
533.40
466.30
% Of Sales
-
19.52%
22.97%
24.37%
23.15%
21.13%
22.58%
19.20%
18.23%
17.26%
16.21%
Manufacturing Exp.
-
1,917.20
1,243.50
1,019.20
864.60
721.20
335.70
391.50
203.70
81.20
62.90
% Of Sales
-
17.16%
15.19%
14.27%
13.72%
13.08%
8.14%
10.06%
6.09%
2.63%
2.19%
General & Admin Exp.
-
359.60
181.50
270.50
182.10
53.00
56.80
21.70
144.60
165.70
131.80
% Of Sales
-
3.22%
2.22%
3.79%
2.89%
0.96%
1.38%
0.56%
4.32%
5.36%
4.58%
Selling & Distn. Exp.
-
221.60
243.80
235.90
266.30
277.50
98.20
107.40
100.80
108.70
118.90
% Of Sales
-
1.98%
2.98%
3.30%
4.23%
5.03%
2.38%
2.76%
3.01%
3.52%
4.13%
Miscellaneous Exp.
-
297.40
107.70
60.40
36.10
37.20
47.40
41.00
50.00
72.70
118.90
% Of Sales
-
2.66%
1.32%
0.85%
0.57%
0.67%
1.15%
1.05%
1.49%
2.35%
2.15%
EBITDA
3,380.10
2,119.50
1,492.60
1,302.10
1,257.00
1,123.80
829.10
979.50
763.10
695.80
687.10
EBITDA Margin
23.13%
18.97%
18.24%
18.23%
19.95%
20.38%
20.11%
25.17%
22.80%
22.52%
23.88%
Other Income
971.80
768.10
690.30
605.20
507.50
414.30
206.20
157.10
83.90
53.10
55.90
Interest
996.20
419.00
67.60
57.70
64.90
70.90
61.50
26.00
29.30
8.90
1.70
Depreciation
1,525.50
1,113.10
814.20
715.10
552.20
447.80
385.10
277.20
248.70
221.00
203.60
PBT
1,824.40
1,355.50
1,301.10
1,134.50
1,147.40
1,019.40
588.70
833.40
569.00
519.00
537.70
Tax
213.40
254.10
211.50
221.50
315.10
212.30
156.90
161.60
142.20
95.70
106.90
Tax Rate
11.70%
23.88%
17.77%
19.31%
25.94%
17.49%
26.65%
19.39%
19.49%
15.33%
19.88%
PAT
1,611.00
462.70
648.40
819.90
777.10
904.40
351.10
595.80
528.70
497.40
413.80
PAT before Minority Interest
1,321.80
643.00
771.60
925.60
899.80
1,001.70
431.80
671.80
587.40
528.40
430.80
Minority Interest
-289.20
-180.30
-123.20
-105.70
-122.70
-97.30
-80.70
-76.00
-58.70
-31.00
-17.00
PAT Margin
11.02%
4.14%
7.92%
11.48%
12.33%
16.40%
8.51%
15.31%
15.79%
16.10%
14.38%
PAT Growth
132.70%
-28.64%
-20.92%
5.51%
-14.08%
157.59%
-41.07%
12.69%
6.29%
20.20%
 
EPS
13.42
3.85
5.40
6.83
6.47
7.53
2.92
4.96
4.40
4.14
3.45

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Shareholder's Funds
17,866.90
8,432.50
7,626.90
6,705.80
6,098.00
5,180.80
4,837.70
4,033.80
3,270.60
3,026.70
Share Capital
600.30
600.30
600.00
600.00
300.00
300.00
100.00
100.00
100.00
100.00
Total Reserves
16,992.60
7,628.10
6,872.80
5,997.00
5,720.80
4,812.30
4,670.20
3,873.00
3,132.70
2,806.20
Non-Current Liabilities
20,742.30
6,802.70
5,496.90
2,684.70
2,122.30
2,006.50
2,304.60
2,421.30
1,377.90
1,262.00
Secured Loans
13,692.30
2,574.30
1,492.40
1,220.80
1,523.50
1,787.00
2,104.30
2,061.00
758.20
580.40
Unsecured Loans
1,598.20
1,424.20
1,469.20
1.40
2.10
2.80
3.90
11.40
11.40
25.80
Long Term Provisions
226.50
91.70
106.20
85.80
66.10
49.30
36.00
29.90
15.00
7.80
Current Liabilities
8,510.70
3,828.00
4,210.10
4,008.00
3,038.50
2,141.30
1,678.30
1,665.70
1,554.70
1,379.60
Trade Payables
3,983.10
1,608.50
1,513.90
1,325.10
1,198.30
1,005.30
739.70
609.80
429.30
347.20
Other Current Liabilities
1,673.80
1,031.20
1,840.20
1,784.40
1,374.70
870.10
698.20
527.10
706.20
612.30
Short Term Borrowings
2,480.20
896.00
594.20
667.60
261.20
130.30
97.20
394.90
261.00
243.50
Short Term Provisions
373.60
292.30
261.80
230.90
204.30
135.60
143.20
133.90
158.20
176.60
Total Liabilities
51,741.80
20,100.70
18,214.60
14,075.80
11,867.70
9,796.30
9,196.70
8,386.60
6,375.40
5,750.60
Net Block
29,467.70
6,569.00
6,363.90
5,971.10
4,471.00
3,699.50
3,625.10
1,748.30
1,629.90
1,525.20
Gross Block
35,321.40
11,233.00
10,220.90
9,147.40
7,095.00
5,873.80
5,436.10
3,403.60
3,034.20
2,701.70
Accumulated Depreciation
5,853.70
4,664.00
3,857.00
3,176.30
2,624.00
2,174.30
1,811.00
1,655.30
1,404.30
1,176.50
Non Current Assets
39,407.80
11,718.40
10,614.20
8,750.80
6,979.20
5,647.70
5,149.00
4,415.70
3,812.80
3,111.80
Capital Work in Progress
7,317.00
4,110.40
2,800.20
2,196.00
1,898.90
1,302.80
839.20
2,239.50
1,676.40
1,205.60
Non Current Investment
742.30
370.20
743.20
108.50
182.50
63.80
188.80
26.80
0.00
64.50
Long Term Loans & Adv.
683.20
483.80
436.40
402.00
335.80
437.20
319.70
350.10
336.90
252.00
Other Non Current Assets
1,197.60
185.00
270.50
73.20
91.00
144.40
176.20
51.00
169.60
64.50
Current Assets
12,334.00
8,382.30
7,600.40
5,325.00
4,888.50
4,148.60
4,047.70
3,970.90
2,562.60
2,638.80
Current Investments
1,326.50
1,217.70
1,208.70
857.60
829.30
611.40
1,065.00
874.70
230.30
700.40
Inventories
4,243.70
2,298.20
1,866.60
1,435.90
1,031.60
722.50
635.30
542.40
452.70
376.60
Sundry Debtors
3,573.20
2,058.20
1,503.30
1,223.70
1,291.80
1,063.90
883.20
714.50
770.50
599.80
Cash & Bank
2,400.10
1,747.50
2,015.40
998.60
1,057.20
1,322.80
1,044.30
1,538.60
937.50
804.40
Other Current Assets
790.50
660.20
713.10
543.60
678.60
428.00
419.90
300.70
171.60
157.60
Short Term Loans & Adv.
456.40
400.50
293.30
265.60
153.10
54.70
24.10
134.70
75.80
81.80
Net Current Assets
3,823.30
4,554.30
3,390.30
1,317.00
1,850.00
2,007.30
2,369.40
2,305.20
1,007.90
1,259.20
Total Assets
51,741.80
20,100.70
18,214.60
14,075.80
11,867.70
9,796.30
9,196.70
8,386.60
6,375.40
5,750.60

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Cash From Operating Activity
1,852.50
1,176.60
1,159.70
1,283.10
1,154.60
662.10
640.00
370.60
210.70
560.70
PBT
897.10
983.10
1,067.70
870.90
1,002.60
610.00
849.70
751.30
624.10
537.70
Adjustment
1,685.00
1,245.00
709.60
921.40
472.60
355.70
204.40
42.00
74.00
134.00
Changes in Working Capital
-501.00
-789.50
-423.80
-165.10
-29.10
-106.50
-211.10
-176.20
-354.00
37.70
Cash after chg. in Working capital
2,081.10
1,438.60
1,353.50
1,627.20
1,446.10
859.20
843.00
617.10
344.10
709.40
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-228.60
-262.00
-193.80
-344.10
-291.50
-197.10
-203.00
-246.50
-133.40
-148.70
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-14,281.80
-1,699.10
-3,624.70
-1,558.90
-713.80
-684.00
-498.50
-1,141.70
-508.70
-938.10
Net Fixed Assets
-260.40
-284.70
-130.90
744.40
-280.60
-177.90
-215.90
-216.90
-57.90
-322.80
Net Investments
-3,990.70
202.20
-456.90
-890.30
107.80
-310.70
-79.30
-3,688.10
328.50
125.80
Others
-10,030.70
-1,616.60
-3,036.90
-1,413.00
-541.00
-195.40
-203.30
2,763.30
-779.30
-741.10
Cash from Financing Activity
13,048.70
242.10
2,564.00
387.60
-241.70
-239.70
-177.50
1,067.60
186.20
426.00
Net Cash Inflow / Outflow
619.40
-280.40
99.00
111.80
199.10
-261.60
-36.00
296.50
-111.80
48.60
Opening Cash & Equivalents
653.70
897.00
824.70
659.30
449.00
710.20
757.50
457.50
557.00
474.00
Closing Cash & Equivalent
1,294.80
653.70
897.00
824.70
659.30
449.00
710.20
757.50
462.60
557.00

Financial Ratios

Consolidated /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Book Value (Rs.)
146.53
68.53
62.27
54.97
50.17
42.59
39.74
33.10
26.93
24.21
ROA
1.79%
4.03%
5.73%
6.94%
9.25%
4.55%
7.64%
7.96%
8.72%
8.47%
ROE
4.98%
9.83%
13.16%
14.26%
18.00%
8.74%
15.37%
16.31%
17.22%
15.68%
ROCE
5.37%
8.30%
11.30%
14.35%
16.11%
8.92%
12.59%
13.93%
15.30%
15.75%
Fixed Asset Turnover
0.48
0.77
0.74
0.78
0.85
0.73
0.89
1.05
1.09
1.12
Receivable days
91.14
79.19
69.67
72.86
77.96
86.05
74.35
80.16
80.09
69.48
Inventory Days
105.87
92.60
84.38
71.47
58.05
60.00
54.81
53.71
48.47
48.54
Payable days
278.58
209.62
230.92
81.60
81.98
87.98
78.68
71.28
58.15
55.73
Cash Conversion Cycle
-81.57
-37.84
-76.87
62.74
54.04
58.07
50.48
62.59
70.42
62.29
Total Debt/Equity
1.01
0.60
0.58
0.40
0.40
0.44
0.48
0.62
0.35
0.30
Interest Cover
3.14
15.54
20.88
19.72
18.12
10.57
33.05
25.90
71.12
317.29

Annual Reports:

FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016
FY 2015
FY 2014

News Update:


  • Biocon signs licensing and supply agreement with Biomm S.A.
    18th Apr 2024, 09:17 AM

    Biomm is Brazil’s first and only biotechnology focused company, providing high quality healthcare to patients with chronic conditions and enhancing access to the latest technologies and treatments

    Read More
  • Biocon’s arm transfers branded formulations business in India to Eris Lifesciences
    3rd Apr 2024, 11:17 AM

    The transaction is completed on April 2, 2024

    Read More
  • Biocon gets approval from MHRA, UK for complex formulation Liraglutide
    28th Mar 2024, 09:39 AM

    Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus

    Read More
  • Biocon’s arm enters into long-term commercial collaboration with Eris Lifesciences
    15th Mar 2024, 14:09 PM

    As a part of this collaboration, Biocon Biologics will continue to leverage Eris’ strong commercial footprint to significantly expand patient access to its world class biosimilars in India

    Read More
  • USFDA concludes inspection at Biocon Campus Site 1 facility of Biocon’s arm
    1st Mar 2024, 09:53 AM

    At the conclusion of this inspection, the agency has issued Form 483s with 4 observations

    Read More
  • Biocon gets penalty of Rs 3.04 crore over GST-related issues
    24th Feb 2024, 14:43 PM

    The company has received an order of adjudication imposing a penalty dated February 22, 2024, from the office of Deputy Commissioner of Commercial Taxes, Divisional GST Office, Bangalore

    Read More
  • Biocon included in S&P Global Sustainability Yearbook 2024
    20th Feb 2024, 12:30 PM

    Biocon’s S&P Global ESG score was 63 versus 52 previously

    Read More
  • Biocon reports consolidated net profit of Rs 753 crore in Q3
    9th Feb 2024, 14:47 PM

    Consolidated total income of the company increased by 49.66% at Rs 4,519.20 crore for Q3FY24

    Read More
  • Biocon’s arm enters into partnership with Sandoz
    9th Feb 2024, 09:22 AM

    The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024

    Read More
  • Biocon - Quarterly Results
    8th Feb 2024, 19:08 PM

    Read More
  • Biocon gets tentative approval from USFDA for Dasatinib tablets
    7th Feb 2024, 10:59 AM

    The approval will further strengthen Biocon’s portfolio of vertically integrated, complex drug products

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.